AngioDynamics Introduces New Biliary Drainage Catheter.Business Editors/Health & Medical Writers QUEENSBURY, N.Y.--(BW HealthWire)--June 5, 2001 AngioDynamics(R), Inc., a wholly-owned subsidiary of E-Z-EM, Inc. (AMEX AMEX See: American Stock Exchange : EZM.A and EZM.B) announced today that it will initiate marketing of its new ABSCESSION(TM)BILIARY DRAINAGE CATHETER in the United States. Commenting on the announcement, Eammon P. Hobbs, President of AngioDynamics, said, "We are pleased to announce the introduction of ABSCESSION(TM) Biliary Drainage Catheters which expand our ABSCESSION(TM) Drainage Catheter product line to cover general drainage and biliary drainage procedures. The ABSCESSION(TM) Drainage Catheter has a multitude of features that should help make it the drainage catheter of choice for interventional practitioners. The distal tip of the catheter is manufactured with a precision process that gives it a smooth dilating taper. This design can help reduce problems with "accordion shaft" when inserting through high-resistance areas. In addition, the catheter shaft is made from an advanced proprietary material blend that provides strength while allowing the catheter to remain supple for patient comfort. The shaft has excellent memory that allows it to maintain its original form after being kinked or crushed, and it is covered with a proprietary surface to reduce friction during insertion and advancement to the drainage site. "Large bore holes in the shaft provide excellent flow for general or biliary drainage procedures. The locking mechanism is simple and easy to use, and the design is low profile and void of sharp corners, another feature designed to help improve patient comfort," said Hobbs. ABSCESSION(TM) BILIARY DRAINAGE CATHETERS are available in 8F through 12F diameters. E-Z-EM, the world's largest manufacturer of contrast agents for gastrointestinal radiology, has developed the only CT injector on the market that can help detect contrast extravasation extravasation /ex·trav·a·sa·tion/ (ek-strav?ah-za´shun) 1. a discharge or escape, as of blood, from a vessel into the tissues; blood or other substance so discharged. 2. the process of being extravasated. , the PercuPump(R) with patented EDA (1) (Electronic Design Automation) Using the computer to design, lay out, verify and simulate the performance of electronic circuits on a chip or printed circuit board. (TM) technology. The Company's wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , AngioDynamics, manufactures a wide range of products, including angiographic, thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. , vascular access vascular access Clinical medicine The ability to enter the vascular system; the ease with which the vascular system can be entered for administering therapy or obtaining blood for testing , and drainage products, as well as stents and medical devices for angioplasty. Enteric enteric /en·ter·ic/ (en-ter´ik) within or pertaining to the small intestine. en·ter·ic adj. 1. Of, relating to, or within the intestine. 2. Products, Inc., another subsidiary, develops, manufactures and markets tests for detection of the ulcer-causing bacterium Helicobacter pylori Helicobacter pylori A gramnegative rod-shaped bacterium that lives in the tissues of the stomach and causes inflammation of the stomach lining. Mentioned in: Indigestion, Ulcers Helicobacter pylori . For additional information, please contact Frank Kerrigon at 1-800-544-4624, ext. 325, (E-mail: fkerrigon@ezem.com) or visit our corporate web site at www.ezem.com. The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, general market conditions, competition and pricing, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q Form 10-Q See 10-Q. for the quarter ended March 3, 2001,as well as its Annual Report on Form 10-K for the year ended June 3, 2000, may affect the actual results achieved by the Company. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion